These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 22995366

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
    Pankuch GA, Seifert H, Appelbaum PC.
    Diagn Microbiol Infect Dis; 2010 Jun; 67(2):191-7. PubMed ID: 20338710
    [Abstract] [Full Text] [Related]

  • 3. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
    Mohanty S, Maurya V, Gaind R, Deb M.
    J Infect Dev Ctries; 2013 Nov 15; 7(11):880-7. PubMed ID: 24240048
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM, Levin AS, De Pedri EH, Fung L, Rossi F, Duboc G, Barone AA, Costa SF.
    Ann Clin Microbiol Antimicrob; 2007 Aug 15; 6():8. PubMed ID: 17697363
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO.
    Int J Antimicrob Agents; 2006 Mar 15; 27(3):224-8. PubMed ID: 16464562
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
    Pankey GA, Ashcraft DS.
    Antimicrob Agents Chemother; 2005 Jul 15; 49(7):2959-64. PubMed ID: 15980375
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T, Anan N, Sugimori G, Watanabe T, Jinushi Y, Yoshida I, Yamano Y.
    Int J Antimicrob Agents; 2009 Dec 15; 34(6):523-8. PubMed ID: 19748767
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of Etest with agar dilution for testing the susceptibility of Pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin.
    Goldstein FW, Ly A, Kitzis MD.
    J Antimicrob Chemother; 2007 May 15; 59(5):1039-40. PubMed ID: 17437963
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ, Acquazzino D, Goering RV, Sammut P, Khalaf N, Hanson ND.
    Clin Infect Dis; 2008 Jun 15; 46(12):e137-41. PubMed ID: 18462098
    [Abstract] [Full Text] [Related]

  • 17. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Bozkurt-Güzel C, Gerçeker AA.
    J Antibiot (Tokyo); 2012 Feb 15; 65(2):83-6. PubMed ID: 22126897
    [No Abstract] [Full Text] [Related]

  • 18. Current therapies for pseudomonas aeruginosa.
    Giamarellou H, Kanellakopoulou K.
    Crit Care Clin; 2008 Apr 15; 24(2):261-78, viii. PubMed ID: 18361945
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
    Kresken M, Körber-Irrgang B, Läuffer J, Decker-Burgard S, Davies T.
    Int J Antimicrob Agents; 2011 Jul 15; 38(1):70-5. PubMed ID: 21514795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.